Abstracts Archive - Page 1688 of 2607 - ACR Meeting Abstracts

Abstract Number: 1331 • 2016 ACR/ARHP Annual Meeting
Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience
Chee Ken Cheah, Shirish Sangle (Joint First Author) and David D'Cruz, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disorder characterized by cartilage inflammation and damage. Chronic RP may lead to sequelae due to cartilage tissue…
Abstract Number: 1332 • 2016 ACR/ARHP Annual Meeting
Severe Complications and Immunosuppressive Treatments in 33 Patients with Relapsing Polychondritis
Toshiki Nakajima¹, Hajime Yoshifuji¹, Chikashi Terao², Kosaku Murakami¹, Nobuo Kuramoto¹, Ran Nakashima¹, Yoshitaka Imura³, Masao Tanaka¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Genomic Center, Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Since relapsing polychondritis (RP) is a rare disease as the prevalence rate is 0.0004% in Japan, its severe complications, prognosis and immunosuppressive therapies have…
Abstract Number: 1333 • 2016 ACR/ARHP Annual Meeting
Relevance of Granulomatous Presentation for the Diagnosis and Outcome of Uveitis: Retrospective Case-Control Study of 251 Patients
Jérôme Hadjadj¹, Thibault Chapron², Manal Assala¹, Sawsen Salah², Bertrand Dunogue¹, Matthieu Groh³, Philippe Blanche¹, Luc Mouthon⁴, Dominique Monnet², Claire Le Jeunne⁴, Antoine Brezin² and Benjamin Terrier³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Ophtalmology, Cochin Hospital, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Findings of ophthalmologic examination can guide the diagnostic management of uveitis. Granulomatous presentation is commonly associated with peculiar causes, including infections, eye-restricted diseases, or…
Abstract Number: 1334 • 2016 ACR/ARHP Annual Meeting
Contribution of Diagnostic Investigations in the Management of Uveitis: Retrospective Analysis of 300 Patients
Jérôme Hadjadj¹, Thibault Chapron², Manal Assala¹, Sawsen Salah², Bertrand Dunogue¹, Matthieu Groh³, Philippe Blanche¹, Luc Mouthon⁴, Dominique Monnet², Claire Le Jeunne⁴, Antoine Brezin² and Benjamin Terrier³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Ophtalmology, Cochin Hospital, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Uveitis represents a diagnostic and therapeutic challenge, as well as an economic one, due to its heterogeneous presentation, multiple underlying causes and lack of…
Abstract Number: 1335 • 2016 ACR/ARHP Annual Meeting
Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study
Eric B. Suhler¹, Glenn J. Jaffe², Quan Dong Nguyen³, Antoine P. Brezin⁴, Manfred Zierhut⁵, Albert Vitale⁶, Mirjam van Velthoven⁷, Alfredo Adan⁸, Lyndell Lim⁹, Michal Kramer¹⁰, Ariel Schlaen¹¹, Eric Fortin¹², Cristina Muccioli¹³, Hiroshi Goto¹⁴, Toshikatsu Kaburaki¹⁵, Anne Camez¹⁶, Alexandra P. Song¹⁷, Martina Kron¹⁶, Samir Tari¹⁷ and Andrew D. Dick¹⁸, ¹Oregon Health & Science University, Casey Eye Institute, and VA Portland Health Care System, Portland, OR, ²Duke University, Durham, NC, ³Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, ⁴Université Paris Descartes, Hôpital Cochin, Paris, France, ⁵Center of Ophthalmology, University of Tuebingen, Tuebingen, Germany, ⁶University of Utah, Salt Lake City, UT, ⁷Rotterdam Eye Hospital, Rotterdam, Netherlands, ⁸Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ⁹Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia, ¹⁰Rabin Medical Center, Petach Tikva, Tel Aviv University, Tel Aviv, Israel, ¹¹Austral University, Buenos Aires, Argentina, ¹²University of Montreal, Montreal, QC, Canada, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Tokyo Medical University, Tokyo, Japan, ¹⁵Ophthalmology, The University of Tokyo School of Medicine, Bunkyo-ku, Japan, ¹⁶Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁷AbbVie Inc., North Chicago, IL, ¹⁸University of Bristol, Bristol Eye Hospital; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London, Institute of Ophthalmology, London, United Kingdom
Background/Purpose: To evaluate the long-term safety and efficacy of adalimumab (Humira®) in patients with non-infectious intermediate, posterior, or panuveitis (NIPPU) in an open-label clinical trial…
Abstract Number: 1336 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for Uveitic Cystoid Macular Edema Refractory to Other Synthetic and Biological Immunosuppressive Drugs. Multicenter Study of 25 Patients
Natalia Palmou-Fontana¹, Vanesa Calvo-Río¹, Marina Mesquida², Alfredo Adan³, M. Victoria Hernández⁴, Emma Beltran⁵, Elia Valls⁶, David Diaz-Valle⁷, Gisela Díaz-Cordovés⁸, Marisa Hernández⁹, L. Martinez-Costa¹⁰, Inmaculada Calvo¹¹, Antonio Atanes-Sandoval¹², Luis Linares¹³, Consuelo Modesto¹⁴, Elena Aurrecochea¹⁵, Miguel Cordero-Coma¹⁶, Lucia C. Domínguez-Casas¹, Carlos Fernández-Díaz¹, Miguel Angel González-Gay¹ and Ricardo Blanco¹⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Ophtalmology, Hospital Clinic, Barcelona, Spain, ³Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁷Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Regional Universitario (Carlos Haya). Málaga. Spain., Málaga, Spain, ⁹Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ¹⁰Hospital Dr. Peset., Valencia, Spain, ¹¹Pediatric Rheumatology, Hospital Univ. La Fe, Valencia, Spain, ¹²Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ¹³Rheumatologist, hospital de la Arrixaca, MURCIA, Spain, ¹⁴Hospital Valle de Hebron, Barcelona, Spain, ¹⁵Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹⁶Departament of Ophthalmology, Hospital de León, León, Spain, ¹⁷Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Our objective was to evaluate the efficacy and safety of Tocilizumab (TCZ) in a series of patients with refractory CME. Methods: A Multicenter…
Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
M. Victoria Hernández¹, Marina Mesquida², Victor Llorens², Maite Sainz de la Maza², Gerard Espinosa³, Ricardo Blanco⁴, Vanesa Calvo⁴, Olga Maiz⁵, Ana Blanco⁶, Juan Ramon De Dios⁷, Pilar Ahijado-Guzman⁸, Enrique Judez⁹, Patricia Tejón¹⁰, M Soledad Peña¹¹, Raimon Sanmarti¹ and Alfredo Adan¹², ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain, ³Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department. Donostia University Hospital, San Sebastian, Spain, ⁶Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ⁷Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁸Avda. Reyes Catolicos, 21, Rheumatology Department. Hospital Infanta Elena, Valdemoro, Madrid, Spain, ⁹Rheumatology Department. Hospital de Albacete, Albacete, Spain, ¹⁰Rheumatology Department. Hospital Universitario General de Castellón, Castellon, Spain, ¹¹Ophtalmology Dpt. Hospital Universitario General de Castellón, Castellon, Spain, ¹²Ophthalmology, Ophthalmology Department. Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…
Abstract Number: 1338 • 2016 ACR/ARHP Annual Meeting
Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease
Deeba Minhas¹, Michele Gandolfi², Jennifer Derebery³, Eric Wilkinson³ and Mariko Ishimori¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Otology, House Clinic, Los Angeles, CA, ³House Clinic, Los Angeles, CA
Background/Purpose: Autoimmune Inner Ear Disease (AIED) is characterized by rapidly progressive sensorineural hearing loss accompanied by tinnitus, with or without vertigo, which may progress to…
Abstract Number: 1339 • 2016 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity
Cassandra Calabrese¹, Apostolos Kontzias¹, Vamsidhar Velcheti² and Leonard H. Calabrese¹, ¹Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, OH, ²Hematology and Oncology, Cleveland Clinic, Cleveland, OH
Background/Purpose: The introduction of immunotherapy with biologic agents targeting immunologic checkpoints (i.e. CTLA4 and PD-1/PDL-1) have yielded impressive gains for cancer patients. These agents…
Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Olga Pinkston¹, Florentina Berianu¹ and Benjamin Wang², ¹Rheumatology, Mayo Clinic, Jacksonville, FL, ²Division of Rheumatology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…
Abstract Number: 1341 • 2016 ACR/ARHP Annual Meeting
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Literature Review
Laura Cappelli¹, Anna Kristina Gutierrez², Ami A. Shah³ and Clifton Bingham III⁴, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD
Rheumatic and Musculoskeletal Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: A Systematic Literature Review Background/Purpose: Immune checkpoint inhibitors (ICI) are effective treatments for advanced…
Abstract Number: 1342 • 2016 ACR/ARHP Annual Meeting
Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports
Noha Abdel-Wahab¹, Mohsin Shah² and Maria Suarez-Almazor³, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: A systematic review of case reports to summarize the existing evidence on the use of checkpoint inhibitors in patients with cancer and preexisting autoimmune…
Abstract Number: 1343 • 2016 ACR/ARHP Annual Meeting
Efficacy of Biological-Targeted Treatments in MDS-Related Systemic Autoimmune Diseases: Multicenter Retrospective Study of 28 Patients
Guillaume Dervin¹, Arsène Mékinian², Jean-Emmanuel Kahn³, louis Terriou⁴, Eric Liozon⁵, Eric Grignano⁶, odile beyne Rauzy⁷, Pascal Godmer⁸, Julien Rossignol⁹, Geraldine Falgarone¹⁰, Laurence Bouillet¹¹, Achille Aouba¹², Philippe Guilpain¹³, David Launay¹⁴, jonathan Broner¹⁵, jerome gillard¹⁶, lionel ades¹⁷, clemence salvado¹⁸, thierry cardon¹⁹, Jean-Charles Piette²⁰, Pierre Fenaux²¹ and Olivier Fain², ¹Medecine Interne Hopital Saint antoine, Paris, France, ²Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ³Internal Medicine, Foch Hospital, Suresnes, France, ⁴médecine interne CHRU lille, Lille, France, ⁵Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ⁶Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, ⁷Medecine interne CHU Purpan, toulouse, France, ⁸CH Vannes, Vannes, France, ⁹haematology, paris, France, ¹⁰Medecine Interne Hopital Avicenne, Bobigny, France, ¹¹CHU, Grenoble, France, ¹²Medecine Interne Hopital Necker, Paris, France, ¹³Medecine interne CHU Montpellier, Montpellier, France, ¹⁴Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁵Medecine Interne CHRU Montpellier, Montpellier, France, ¹⁶Medecine Interne CHRU Lons le Saunier, Lons, France, ¹⁷Service Hématologie Hopital d'Avicennes, Bobigny, France, ¹⁸Service d'hématologie CHU Mondor, Creteil, France, ¹⁹Medecine interne CHU Lille, lille, France, ²⁰Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²¹Hematologie Hopital Avicenne, Bobigny, France
Background/Purpose: This study analyze the safety and efficiency of biologics (TNF-α antagonists, tocilizumab, rituximab and IL-1 inhibitors) in patients with autoimmune systemic diseases (SAIDs) associated…
Abstract Number: 1344 • 2016 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Severe Pulmonary Hemorrhage Related to Systemic Disease: French Multicentric Study
Adrien Mirouse¹, Antoine Parrot², Jacques Cadranel³, Eric Mariotte⁴, Julien Mayaux⁵, Nicolas Bréchot⁶, Mathieu Vautier⁷, Etienne de Montmollin⁸, Nicolas de Prost⁹, Patrice Cacoub¹⁰ and David Saadooun¹⁰, ¹Service de médecine interne, Hôpital Saint-Antoine, Paris, France, ²Service de pneumologie, Hôpital Tenon, 75020, France, ³Service de pneumologie, Hôpital Tenon, Paris, France, ⁴Service de réanimation médicale, Hôpital Saint-Louis, Paris, France, ⁵Service de pneumologie et réanimation médicale, Hôpital Pitié-Salpêtrière, Paris, France, ⁶Service de réanimation médicale, Hôpital Pitié-Salpêtrière, Paris, France, ⁷Service de médecine interne, CHU de Caen, Caen, France, ⁸Service de réanimation médicale, Hôpital Delafontaine, Saint-Denis, France, ⁹Service de réanimation médicale, Hôpital Henri Mondor, Créteil, France, ¹⁰Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France
Background/Purpose: pulmonary hemorrhage (PH) may complicate systemic disease. The main objective of this study was to describe characteristics, treatment and outcome of patients presenting severe…
Abstract Number: 1345 • 2016 ACR/ARHP Annual Meeting
Undifferentiated Connective Tissue Disease: A 121 Patients Audit Focusing on Initial Diagnosis and Changes over Time
Maria Leandro^1,2 and Raluca Ionescu^3,4, ¹Rheumatology, University College London Hospitals, London, United Kingdom, ²University College London, London, Uruguay, ³University College London Hospitals, London, United Kingdom, ⁴Sfanta Maria Hospital, Bucharest, Romania
Background/Purpose: The diagnosis of Undifferentiated Connective Tissue Disease (UCTD) has raised controversy over the years regarding making the diagnosis, evolution and prognosis. Le Roy et…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].